Sangamo Therapeutics, Inc. Stock News

Sangamo Therapeutics, Inc. received IND clearance to initiate a phase 1/2 study for ST-503 targeting idiopathic small fiber neuropathy, a type of chronic neuropathic pain condition. SGMO entered a deal with Astellas, allowing the use of its STAC-BBB capsid for the development of up to 5 neurological disorders; a $20 million upfront payment & $1.3 billion milestone payments. The global Neuropath...

- Agreement grants Astellas rights to employ Sangamo's novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets - - Sangamo to receive a $20 million upfront license fee and is eligible to earn up to $1.3 billion in additional licensed target fees and milestone payments across all five potential disease targets, as well as tiered royalties on potential net sales ...

RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES U.S. FDA CLEARANCE OF IND APPLICATION FOR ST-503 FOR THE TREATMENT OF IDIOPATHIC SMALL FIBER NEUROPATHY.

Sangamo Therapeutics, Inc. (SGMO) Q3 2024 Earnings Call Transcript

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results.

RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES THIRD QUARTER 2024 CONFERENCE CALL AND WEBCAST.

Positive Type B meeting held with FDA, whereby U.S. agency stated that the phase 1/2 STAAR study using isaralgagene civaparvovec targeting Fabry Disease patients would be enough for Accelerated Approval. The global Fabry Disease treatment market size is expected to be worth $3.34 billion by 2030. Data from the phase 1/2 STARR study, using isaralgagene civaparvovec targeting patients with Fabry ...

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025.